20
NOV
2017

NW Bio Issues Notice Of Proposed Agreement To Settle Shareholder Derivative Lawsuit

Posted By :
Comments : Off
Notice Being Issued to Fulfill Settlement Agreement Condition    BETHESDA, Md., November 20, 2017 ­– Northwest Biotherapeutics, Inc. (OTCQB: NWBO) (“NW Bio”), a U.S. biotechnology company developing DCVax® personalized immune therapies for operable and inoperable solid tumor cancers, is pleased to have reached an agreement to settle the derivative lawsuit captioned Wells v. Powers, et al., which was filed on November 28, 2016 in the Circuit...
Read More
25
OCT
2017

NW Bio Reports Favorable Results and Progress In Resolving Lawsuits

Posted By :
Comments : Off
3 Cases Substantially Completed, 4th Case Pending Completion,  No Monetary Damages Contemplated   Bethesda, MD, October 24, 2017 – Northwest Biotherapeutics, Inc. (OTCQB: NWBO) (“NW Bio”), a U.S. biotechnology company developing DCVax® personalized immune therapies for operable and inoperable solid tumor cancers, is pleased to report meaningful progress in resolving four lawsuits that were brought against it as reported in the Company’s...
Read More
17
OCT
2017

NW Bio Leases Out Warehouse On UK Property to Major Commodities Distribution Firm

Posted By :
Comments : Off
Lease Includes Substantial Refurbishment and Approximately $6 Million Revenues Over 5 Years   BETHESDA, Md., October 17, 2017 – Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced it has leased an existing warehouse on the Company’s property in the UK to Commodity Centre Group, a commodity storage and distribution firm...
Read More
20
SEP
2017

NW BIO Announces Registered Direct Offering Of $1.75 Million

Posted By :
Comments : Off
BETHESDA, Md., September 20, 2017 – Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has entered into definitive agreements with institutional investors for a registered direct offering with gross proceeds of $1.75 million. In the transaction, the Company will sell approximately 8.75 million shares of common stock...
Read More
01
SEP
2017

DCVax® Clinical Program Updates Presented By Dr. Marnix Bosch At Boston Scientific Conference

Posted By :
Comments : Off
DCVax®-L Phase III GBM Trial & DCVax-Direct Phase I/II Updates;  Overview Of A Broader Range Of DC Vax Public Data     BETHESDA, Md., September 1, 2017 – Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that Dr. Marnix L. Bosch, MBA, PhD and Chief Technical Officer of NW Bio presented an update on the Phase III Trial o...
Read More